SCHEMBL2997461

SCHEMBL2997461

COc1cc(C(C)=O)ccc1OC(C)=O

nearest known ligand 0.77

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 3/20 0.77
ALDH1A1 P00352 3/20 0.62
RAB9A P51151 2/20 0.62
GAA P10253 2/20 0.62
KDM4E B2RXH2 1/20 0.62
PKM P14618 2/20 0.60
NPC1 O15118 1/20 0.60
SMN1; SMN2 Q16637 1/20 0.60
L3MBTL1 Q9Y468 1/20 0.60
CYP1A2 P05177 1/20 0.58
CYP3A4 P08684 1/20 0.58
CYP2C9 P11712 1/20 0.58
CYP2C19 P33261 1/20 0.58
MAPT P10636 1/20 0.57
NR3C1 P04150 1/20 0.57
CA12 O43570 1/20 0.56
CA1 P00915 1/20 0.56
CA2 P00918 1/20 0.56
CA4 P22748 1/20 0.56
CA6 P23280 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10830995 0.93 TSHR (0.67) TSHRALDH1A1RAB9AGAAKDM4E
SCHEMBL6550416 0.90 TSHR (0.75) TSHRALDH1A1RAB9AGAAKDM4E
SCHEMBL76834 0.88 TSHR (0.73) TSHRALDH1A1GAASMN1; SMN2L3MBTL1
SCHEMBL29399077 0.88 TSHR (0.73) TSHRALDH1A1GAASMN1; SMN2L3MBTL1
SCHEMBL27753902 0.88 TSHR (0.73) TSHRALDH1A1GAASMN1; SMN2L3MBTL1
SCHEMBL111732 0.87 TSHR (1.00) TSHRALDH1A1RAB9AGAAKDM4E
SCHEMBL23467802 0.86 TSHR (0.73) TSHRALDH1A1RAB9AGAAKDM4E
SCHEMBL30743049 0.86 TSHR (0.73) TSHRALDH1A1RAB9AGAAKDM4E
SCHEMBL17184498 0.86 TSHR (0.73) TSHRALDH1A1RAB9AGAAKDM4E
SCHEMBL13775494 0.86 TSHR (0.73) TSHRALDH1A1RAB9AGAAKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102459291-A Neuroprotective compounds and their use MCW RES FOUND INC (US) 2012-05-16 CN claimed
EP-4251708-B1 METHOD FOR PRODUCING A HIGH-PHENOLIC-CONTENT BIOOIL THE UNIV OF NEW BRUNSWICK (CA) 2026-02-11 EP disclosed
US-20260027136-A1 CANNABIS BASED THERAPEUTIC AND METHOD OF USE YUZU LV LLC (US) 2026-01-29 US disclosed
US-12458653-B2 Cannabis based therapeutic and method of use YUZU LV LLC (US) 2025-11-04 US disclosed
US-12303488-B2 Cannabis based therapeutic and method of use YUZU LV LLC (US) 2025-05-20 US disclosed
EP-4417252-A2 CANNABIS BASED THERAPEUTIC AND METHOD OF USE Yuzu LV LLC (US) 2024-08-21 EP disclosed
US-20230365764-A1 METHOD FOR PRODUCING A HIGH-PHENOLIC-CONTENT BIOOIL THE UNIVERSITY OF NEW BRUNSWICK (CA) 2023-11-16 US disclosed
US-20230346739-A1 CANNABIS BASED THERAPEUTIC AND METHOD OF USE YUZU LV LLC 2023-11-02 US disclosed
US-20230293480-A1 CANNABIS BASED THERAPEUTIC AND METHOD OF USE YUZU LV LLC 2023-09-21 US disclosed
US-20230293555-A1 COMPOSITIONS COMPRISING CANNABIDIOL AND FLAVANONES YUZU LV LLC 2023-09-21 US disclosed
EP-2069321-A1 NOVEL BENZOFURAN TYPE DERIVATIVES, A COMPOSITION COMPRISING THE SAME FOR TREATING OR PREVENTING COGNITIVE DYSFUNCTION AND THE USE THEREOF Digital Biotech Co., Ltd. (KR) 2009-06-17 EP disclosed
WO-2008041826-A1 NOVEL BENZOFURAN TYPE DERIVATIVES, A COMPOSITION COMPRISING THE SAME FOR TREATING OR PREVENTING COGNITIVE DYSFUNCTION AND THE USE THEREOF DIGITAL BIOTECH CO., LTD (KR) 2008-04-10 WO disclosed
US-20070259333-A1 NOVEL ZWITTERIONIC DYES FOR LABELING IN PROTEOMIC AND OTHER BIOLOGICAL ANALYSES MONTANA STATE UNIVERSITY (US) 2007-11-08 US disclosed
US-20070259333-A1 NOVEL ZWITTERIONIC DYES FOR LABELING IN PROTEOMIC AND OTHER BIOLOGICAL ANALYSES MONTANA STATE UNIVERSITY (US) 2007-11-08 US disclosed
CN-1923790-A Kutkin derivative, preparation method and application thereof UNIV JINAN (CN) 2007-03-07 CN disclosed
US-20070037739-A1 Compounds useful in coating stents to prevent and treat stenosis and restenosis MEDLOGICS DEVICE CORPORATION (US) 2007-02-15 US disclosed
US-20070037739-A1 Compounds useful in coating stents to prevent and treat stenosis and restenosis MEDLOGICS DEVICE CORPORATION (US) 2007-02-15 US disclosed
US-20070037739-A1 Compounds useful in coating stents to prevent and treat stenosis and restenosis MEDLOGICS DEVICE CORPORATION (US) 2007-02-15 US disclosed
US-20070032477-A1 Pteridine derivatives useful for making pharmaceutical compositions 4 AZA BIOSCIENCE NV (BE) 2007-02-08 US disclosed
WO-2004069201-A2 COMPOUNDS USEFUL IN COATING STENTS TO PREVENT AND TREAT STENOSIS AND RESTENOSIS MEDLOGICS DEVICE CORPORATION (US) 2004-08-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260027136-A1 CANNABIS BASED THERAPEUTIC AND METHOD OF USE CNR1, CNR2, OPRM1 TSHR 4394/4885ALDH1A1 1420/4885RAB9A 1595/4885
US-20070032477-A1 Pteridine derivatives useful for making pharmaceutical compositions TPMT, TYMS, TNF TSHR 4732/4885ALDH1A1 1733/4885RAB9A 1816/4885
US-20070037739-A1 Compounds useful in coating stents to prevent and treat stenosis and restenosis CAD, DBNL, DCAF15 TSHR 4614/4885ALDH1A1 3734/4885RAB9A 4110/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.